Compare UBCP & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | PSTV |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 80.4M |
| IPO Year | N/A | N/A |
| Metric | UBCP | PSTV |
|---|---|---|
| Price | $13.85 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 4.3K | ★ 11.0M |
| Earning Date | 02-06-2026 | 10-30-2025 |
| Dividend Yield | ★ 6.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | $5.59 | $12.05 |
| P/E Ratio | $10.37 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $0.16 |
| 52 Week High | $15.64 | $2.31 |
| Indicator | UBCP | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 25.61 |
| Support Level | $13.55 | $0.26 |
| Resistance Level | $13.98 | $0.31 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 31.02 | 7.63 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).